Efficient and effective adaptive radiotherapy
Dr N Hardcastle, Dr A Yeo
Applications accepted all year round
Approximately 40% of cancer patients benefit from radiotherapy. Radiotherapy involves highly targeted radiation beams directed at the tumour, whilst avoiding surrounding normal tissues.
Enhancing Radiotherapy Outcomes for Oesophageal Cancer (Deadline extended)
Dr M Hawkins, Prof F Van den Heuvel
30 April 2019
Inhibition of ATR (a DNA damage checkpoint kinase) is currently being evaluated with radiotherapy and chemoradiation in patients with oesophageal cancer in the Cancer Research UK/MRC funded CHARIOT clinical study, whilst dose escalation is being evaluated in the SCOPE 2 clinical study.
Nano4CaRE: (Nanoparticles for Cancer Radiotherapy Enhancement)
Dr N Bricklebank, Dr N Cross, Dr R Leyland
12 April 2019
TPP-functionalisation will promote the uptake of nanoparticles by cancer cells. Radiosensitisation will be improved by varying the size and ligand density of the TPP-nanoparticles.